MolecularMD Licenses NYU, MSKCC Patents to Develop PGx Test for BRAF Mutation
October 21, 2010
MolecularMD Licenses NYU, MSKCC Patents to Develop PGx Test for BRAF Mutation
The licensing agreement pertains to a patent describing the diagnostic use of a fluorescent-based, allele-specific PCR assay to amplify the V600E mutation.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Italian Team Shows LNA-Modified qPCR Method Outperforms Sanger Sequencing for KRAS, BRAF Mutations
May 17, 2012 / PCR Insider - MolecularMD Licenses IP from NYU, MSKCC
October 19, 2010 / GenomeWeb Daily News - ARUP Labs Develops Modified Allele-Specific qPCR Assay for BRAF V600E Mutation
January 24, 2013 / PCR Insider - Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
June 8, 2011 / Pharmacogenomics Reporter - Thermo Fisher Contacted Life Tech in 2011 about Possible Acquisition; Document Discloses Other Bidders
May 22, 2013 / GenomeWeb Daily News